Navigation Links
LifeCycle Pharma to Initiate Phase II Clinical Trial of LCP-Tacro for Organ Transplantation

LifeCycle Pharma will initiate a Phase II clinical trial of LCP-Tacro for the prevention of organ rejection in kidney transplant patients following the update of its initial Investigational New Drug Application (IND) in the United States (U.S.)

LifeCycle Pharma has also reached protocol agreement with the U.S. Food and Drug Administration (FDA) for its first Phase II trial in kidney transplant recipients.

LifeCycle Pharma A/S (OMX:LCP) today announced it will initiate a Phase II clinical trial program using LCP-Tacro to prevent organ rejection in kidney transplant patients. The clinical trial protocol has been reviewed by the FDA, and LifeCycle Pharma has revised it to be in line with FDA recommendations. As a result, LifeCycle Pharma expects to initiate a Phase II clinical trial soon.

The trial is designed as a conversion study in stable kidney transplant recipients, with patients being switched to LCP-Tacro once-a-day from Prograf(R) twice-a-day. Up to 60 patients will be investigated at 10-12 sites in the U.S. and Canada, and the initial clinical trial results are expected by year end 2007, or early 2008. This study is considered to form the basis for initiation of a subsequent Phase III program in de-novo kidney transplant recipients.

A Phase II clinical study in liver transplant recipients is expected to follow this year.

"The initiation of the Phase II study using LCP-Tacro is a step forward in the development of our organ transplantation franchise," said Dr. Flemming Ornskov, President and CEO of LifeCycle Pharma. "We are encouraged by the progress LifeCycle Pharma has made, and eager to advance LCP-Tacro to Phase II clinical trials," added Dr. Ornskov.

"This is the start of an exciting clinical development program. LCP-Tacro will bring the convenience of once-daily administration of tacrolimus and may optimize outcomes after kidney transplantation," said Dr. Shamkant Mulg aonkar, Chief of the Transplant Division at St. Barnabas Healthcare System, Livingston, New Jersey, USA and a clinical investigator in the first Phase II study.


'"/>




Related medicine news :

1. LifeCycle Pharma Forms Scientific Advisory Board in Solid Organ Transplantation
2. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
3. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
4. Pharma cos must forge Strategic alliances
5. Medicis Pharmaceutical company enters pediatric market
6. Pharma majors gear to supply anti-anthrax drug
7. Pharmacies in for a dose of bitter medicine
8. Andhra Pradesh to set up Pharma City
9. Sun Pharma to launch chiral version of omeprazole soon
10. AAI Pharma Files Lawsuit Against Dr. Reddys Laboratories
11. Pharmacia may take 51.5 percent Abbott stake
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/8/2016)... ... 08, 2016 , ... Stephanie Hebert Insurance Agency, serving families ... new charity campaign. As part of their ongoing community involvement program, funds are ... that children deserve a voice, and in the spirit of neighbors helping neighbors ...
(Date:2/8/2016)... ... 2016 , ... Tingley Rubber Corporation , a leading ... range of unique and advantaged protective solutions to a growing and dynamic ... customer service and marketing support. A new distribution center in Brampton, Ontario will ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... networking and relationship-marketing firm, announced today that nominations will be accepted February ... (ISE®) West Awards. , Awards include the Information Security Executive® of ...
(Date:2/8/2016)... ... 2016 , ... GrassrootsHealth published data from its D*action public ... in the GrassrootsHealth cohort with substantially higher vitamin D levels than a cohort ... states Carole Baggerly, Director of GrassrootsHealth, “the safety and benefits of vitamin ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... The ... annually in this country. The AutismOne 2016 Conference, which is being held May 25-29 ... often won’t hear elsewhere about helpful interventions and causes of chronic illness in children. ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... 2016 http://www.researchandmarkets.com/research/fqx6nz/global_skin ) ... Skin Protective Equipment Market 2016-2020" report to ... ) has announced the addition of the ... to their offering. --> ... the addition of the "Global Skin Protective ...
(Date:2/8/2016)... , Feb. 8, 2016  A research team ... scientists has discovered details of how the abnormal breakage ... a particularly aggressive form of acute lymphoblastic leukemia (ALL). ... which genetic mutations trigger overproduction of immature cells, called ... The discoveries of the malfunction underlying the type called ...
(Date:2/8/2016)... -- As part of a major growth and expansion initiative, Dune ... Lori Chmura as President of Dune Inc., its U.S. ... extensive experience in the medical device space will play a ... --> --> In her ... marketing and operational functions in the U.S. She is tasked ...
Breaking Medicine Technology: